Alnylam Announces Manufacturing Agreement With Dowpharma

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and Dowpharma, a business unit of The Dow Chemical Company, announced an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular degeneration and respiratory syncytial virus infection. Dowpharma will manufacture short interfering RNAs (siRNAs), the molecules that induce RNAi, for use in clinical trials.

Drug Discovery Online (http://www.drugdiscoveryonline.com/content/news/article.asp?DocID=%7b8D4661B5-34A7-40F6-BF6F-4DBD8B5B57D8%7d&Bucket=Current%2BHeadlines&VNETCOOKIE=NO)